<PAGE>
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
FORM 10-K/A
[X]ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1995
OR
[_]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
COMMISSION FILE NUMBER 0-15246
ORGANOGENESIS INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 04-2871690
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NUMBER)
150 DAN ROAD, CANTON, MA 02021
(ADDRESS OF PRINCIPAL EXECUTIVE (ZIP CODE)
OFFICES)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (617) 575-0775
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
<TABLE>
<CAPTION>
NAME OF EACH
EXCHANGE
TITLE OF EACH CLASS ON WHICH REGISTERED
------------------- -----------------------
<S> <C>
Common Stock, $.01 value.......................... American Stock Exchange
</TABLE>
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT: NONE
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes [X] No [_]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein and will not be contained, to
the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [_]
As of March 1, 1996, the approximate aggregate market value of voting stock
held by non-affiliates of the registrant was $214,652,097, based on the last
reported sale price of the Company's Common Stock on the American Stock
Exchange as the close of business on March 1, 1996. There were 13,961,112
shares of Common Stock outstanding as of March 1, 1996.
DOCUMENTS INCORPORATED BY REFERENCE
<TABLE>
<CAPTION>
PART OF FORM 10-K
DOCUMENT INTO WHICH INCORPORATED
-------- -----------------------
<S> <C>
Portions of the Registrant's Proxy Statement for the
1996 Annual Meeting of Stockholders.................. III
</TABLE>
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
Organogenesis Inc.
/s/ Herbert M. Stein
BY: _________________________________
HERBERT M. STEIN
CHAIRMAN AND CHIEF EXECUTIVE
OFFICER
Date: April 17, 1996
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<S> <C> <C>
/s/ Herbert M. Stein Chairman, Chief April 17, 1996
- ------------------------------------- Executive Officer
Herbert M. Stein and Director
(Principal
executive officer)
/s/ David T. Rovee President, Chief April 17, 1996
- ------------------------------------- Operating Officer
David T. Rovee and Director
/s/ Richard S. Cresse Director April 17, 1996
- -------------------------------------
Richard S. Cresse
/s/ William J. Hopke Director April 17, 1996
- -------------------------------------
William J. Hopke
/s/ Anton E. Schrafl Director April 17, 1996
- -------------------------------------
Anton E. Schrafl
/s/ Bjorn Olsen Director April 17, 1996
- -------------------------------------
Bjorn Olsen
/s/ Marguerite A. Piret Director April 17, 1996
- -------------------------------------
Marguerite A. Piret
/s/ Donna L. Abelli Vice President, April 17, 1996
- ------------------------------------- Chief Financial
Donna L. Abelli Officer,Treasurer
and Secretary
</TABLE>
32
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<CIK> 0000779733
<NAME> ORGANOGENESIS INC.
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1995
<PERIOD-START> JAN-01-1995
<PERIOD-END> DEC-31-1995
<CASH> 2,569,256
<SECURITIES> 11,151,564
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 14,277,887
<PP&E> 10,099,517
<DEPRECIATION> 5,157,526
<TOTAL-ASSETS> 19,303,900
<CURRENT-LIABILITIES> 1,392,069
<BONDS> 0
0
0
<COMMON> 137,324
<OTHER-SE> 77,340,739
<TOTAL-LIABILITY-AND-EQUITY> 19,303,900
<SALES> 0
<TOTAL-REVENUES> 626,917
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 13,364,123
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (12,737,206)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (12,737,206)
<EPS-PRIMARY> (1.02)
<EPS-DILUTED> (1.02)
</TABLE>
